| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b topline data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1b topline data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1b topline data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Kazia Therapeutics Limited
$13.2
-0.21 (-1.53%)
D 38Pipeline Score Overvalued Biotech · Clinical
Market Cap
149.64 M
EPS
-6.82
P/E Ratio
-
Value Trade
3.02 M
-8.21 %
Week
8.11 %
1 Month
5.52 %
3 Month
101.83 %
6 Month
-97.03 %
5 Year
-99.41 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
61.80 K
52 Week Range
4.86 - 17.40
% held by Insiders
14.01 %
% held by Institutions
36.49 %
Enterprise Value
108.60 M
Total Shares
11.34 M
Short %
6.91 %
Float Shares
9.75 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kazia Therapeutics Limited
458Total events
13Upcoming
104Tier-1 (high impact)
2017 – 2027Coverage
Upcoming catalysts 2
TBD
T2IND Submission
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
●Composition Patent FiledPaxalisibFiledIP / Competition
Subscribe to view catalyst details
TBD
▲Preclinical PoCPaxalisibFiledPreclinical
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-31 | NDL2 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-03-31 | NDL2 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-03-31 | NDL2 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
D38
Pipeline Score $73M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.5x
rNPV / MCap Top 58%
Micro Cap (rank 393 of 933)
Percentile RankKazia Therapeutics Limited faces pipeline headwinds (38/100), with $868M risk-adjusted pipeline value, led by Abemaciclib in CDK Gene Mutation (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abemaciclib Small molecule | CDK Gene Mutation | Phase 2 | NCT03994796 | 10% | $192M | ACTIVE NOT_RECRUITING | 50 | - | - | Jun 1, 2028 | - | Apr 13, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
paxalisib Fast TrackOrphanRare Pediatric | late-stage metastatic triple-negative breast cancer | Phase 1b | 2026-01-28 | two partial responses; one complete metabolic response | Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Read More | |
paxalisib Fast TrackOrphanRare Pediatric | late-stage metastatic triple-negative breast cancer | Phase 1b | 2026-01-28 | two partial responses; one complete metabolic response | Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Read More | |
paxalisib Fast TrackOrphanRare Pediatric | late-stage metastatic triple-negative breast cancer | Phase 1b | 2026-01-28 | two partial responses; one complete metabolic response | Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KZIA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KZIA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KZIAKazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
Kazia Therapeutics has filed a provisional patent for a new therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer (TNBC). Supported by promising preclinical data, the strategy involves the use of paxalisib, which has shown a significant reduction in residual disease and lung metastasis. The company is looking to broaden the clinical development of paxalisib based on these findings.
Read more →KZIA▼ -6.1%on this news
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Kazia Therapeutics has appointed James Levine as Chief Financial Officer, effective June 1, 2026. Levine brings over 20 years of experience in financial leadership within the biotech sector. His role is expected to support Kazia's advancement of its lead asset, paxalisib, and the development of its oncology pipeline. The company is targeting multiple cancer indications with promising clinical trials underway.
Read more →KZIA▼ -8.4%on this news
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics has announced an expansion of its ongoing Phase 1b trial for paxalisib in advanced triple negative breast cancer, increasing patient enrollment from 12 to 36. This decision follows positive safety and tolerability data. The trial aims to assess the efficacy of paxalisib in combination with pembrolizumab and chemotherapy, with updates expected throughout 2026 and 2027.
Read more →KZIANASDAQ: KZIA | X: @KaziaTx Beyond Inhibition. Reprogramming Cancer Control. 2026 Corporate Overview April 2026 This presentation contains forward - looking statements, which can generally be identified as such by the use
Kazia Therapeutics is a clinical-stage oncology company focused on developing next-generation therapies for high-need cancers. The company highlighted its lead asset, paxalisib, a dual PI3K/mTOR inhibitor, and other candidates like NDL2 and EVT801 in its corporate overview. With ongoing trials and approximately $46 million in cash, Kazia is positioned to continue its research and clinical programs into 2029. The company aims to redefine cancer treatment by going beyond conventional methods and targeting fundamental drivers of cancer biology.
Read more →KZIA▲ +5.7%on this news
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics has appointed Dr. Sudha Rao as Chief Scientific Officer to lead its oncology platform. Dr. Rao, a pioneer in epigenetic therapies, will oversee research and development, focusing on advancing Kazia's pipeline, including paxalisib and novel PD-L1 degradation strategies. Her leadership is expected to strengthen Kazia's integrated oncology strategy.
Read more →KZIA▲ +5.2%on this news· ran to +23% by day 3shared move
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The lead candidate, MSETC, aims to restore immune signaling in tumors resistant to immunotherapy. This program is part of Kazia's strategy to address cancer treatment resistance through innovative therapies. The SETDB1 program is currently in preclinical development with a clear path toward IND-enabling studies.
Read more →KZIANASDAQ: KZIA | X: @KaziaTx Beyond Inhibition. Reprogramming Cancer Control. 2026 Corporate Overview March 2026 1 This presentation contains forward-looking statements, which can generally be identified as such by the use
Kazia Therapeutics (KZIA) provided an overview of its corporate strategy focusing on innovative cancer treatments. The company is developing several promising assets, including paxalisib, a dual PI3K/mTOR inhibitor for aggressive cancers. Kazia aims to redefine cancer treatment by reprogramming the biology of tumors, addressing resistance mechanisms, and enhancing patient outcomes. Their financial health appears robust, with sufficient funds to support their developmental initiatives into 2029. However, the company acknowledges inherent risks in clinical development and potential impacts from economic conditions.
Read more →KZIAKazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2025 Kazia Therapeutics Limited Directors' report 31 December 2025 The directors present their report, together with the financial statements
Kazia Therapeutics Limited released its half-yearly financial report for the period ending December 31, 2025. The report highlights a significant loss of $12,552,490, an increase from $10,453,811 the previous year. Despite the financial setbacks, the company made notable advancements in clinical trials, particularly with paxalisib, which is being explored in multiple breast cancer settings. Kazia has also secured substantial funding through private placements aimed at supporting its ongoing research and development efforts.
Read more →KZIAKazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Kazia Therapeutics has announced significant preclinical findings for NDL2, a novel nuclear PD-L1 degrader. This therapy targets a newly identified driver of immunotherapy resistance, showing promising results in reducing tumor volume and enhancing anti-tumor activity. The data suggest NDL2 could address limitations of existing PD-1/PD-L1 therapies, with plans for clinical trials in 2027.
Read more →KZIA▼ -8.3%on this newsshared move
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Kazia Therapeutics has reported promising preliminary results from its Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer. Three patients treated with paxalisib-based regimens exhibited significant clinical responses, including two partial responses and one complete metabolic response. The trial aims to evaluate the safety and efficacy of paxalisib in combination with standard therapies.
Read more →KZIAKazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Kazia Therapeutics will participate in the J.P. Morgan Healthcare Conference, focusing on investor relations and business development. The company anticipates a clinical update on paxalisib for triple-negative breast cancer by the end of January. This update may provide critical insights into treatment responses and biomarker analyses, further supporting the drug's potential in metastatic breast cancer.
Read more →KZIAKazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to...
Kazia Therapeutics announced participation in the J.P. Morgan Healthcare Conference week, where CEO John Friend will engage with investors and collaborators. The company anticipates a clinical update on paxalisib's Phase 1b trial for triple-negative breast cancer before the end of January. This update may provide significant insights into treatment responses and biomarker analyses.
Read more →KZIA▼ -8%on this news· ran to -30% by day 3
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Kazia Therapeutics Limited has announced that it has regained full compliance with Nasdaq listing standards following a $50 million private placement. The financing significantly bolstered the company's balance sheet and equity position. With this restored compliance, Kazia is set to focus on advancing its clinical-stage oncology pipeline, which includes ongoing development of its lead program, paxalisib. The successful resolution also cancels a previously scheduled hearing before the Nasdaq Hearings Panel, signifying enhanced clarity for investors.
Read more →KZIA▼ -17.8%on this news· ran to -39% by day 3
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
Kazia Therapeutics has announced promising new findings regarding paxalisib's efficacy in treating advanced breast cancer, particularly in triple-negative and HER2-positive populations. Data presented at the 2025 San Antonio Breast Cancer Symposium highlights paxalisib's ability to reduce circulating tumor cells and enhance immune response. The results suggest that paxalisib may address gaps left by existing therapies and could expand its utility across various breast cancer subtypes.
Read more →KZIA▲ +9.9%on this news· ran to +64% by day 3
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Kazia Therapeutics Limited has announced a $50 million private placement of equity securities to institutional investors. The funds will be used to advance the clinical development of its lead program, paxalisib, and for general corporate purposes. The transaction is expected to close on December 3, 2025, subject to customary conditions.
Read more →KZIA▲ +34.4%on this news· ran to +47% by day 3
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
Kazia Therapeutics announced an initial immune-complete response in a stage IV TNBC patient treated with paxalisib and pembrolizumab. This follows a significant tumor reduction and highlights the potential of the combination therapy. The company also provided a business update, including upcoming presentations at major oncology conferences and plans for regulatory discussions regarding their GBM program. However, Kazia faces challenges with Nasdaq compliance.
Read more →KZIAKazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Kazia Therapeutics intends to request a Type C meeting with the FDA to discuss overall survival data from its paxalisib treatment in newly diagnosed glioblastoma patients. The company seeks feedback on a potential regulatory pathway aligned with the FDA's Project FrontRunner initiative. Kazia aims to initiate a Phase 3 confirmatory study prior to submitting a New Drug Application (NDA).
Read more →KZIAKazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
Kazia Therapeutics has entered into a collaboration and in-licensing agreement with QIMR Berghofer for the development of NDL2, a first-in-class PD-L1 protein degrader. This innovative therapy aims to target resistant forms of PD-L1, potentially overcoming immunotherapy resistance in cancers like triple-negative breast cancer and non-small cell lung cancer. Preclinical studies have shown promising results, with significant tumor reduction and no observed toxicity.
Read more →KZIA▼ -6.9%on this newsshared move
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
Kazia Therapeutics reported an 86% reduction in tumor burden in a metastatic TNBC patient treated with paxalisib in an expanded-access case. The patient, previously diagnosed with TNBC, underwent a combination of immunotherapy and chemotherapy. This case aligns with Kazia's ongoing Phase 1b trial, which evaluates paxalisib alongside Keytruda and chemotherapy for advanced breast cancer.
Read more →KZIAKazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Kazia Therapeutics is collaborating on a three-year MRFF project focused on developing an AI-driven platform for optimizing treatment strategies for diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG). The project will utilize Kazia's investigational drug, paxalisib, which has shown promise in clinical studies. This initiative aims to enhance treatment outcomes for pediatric patients suffering from these aggressive brain cancers.
Read more →KZIAKazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
Kazia Therapeutics has reported promising results from an ex vivo study demonstrating that paxalisib monotherapy can completely disrupt circulating tumor cell clusters in patients with Stage IV HER2-positive breast cancer. This finding extends the drug's potential beyond triple-negative breast cancer and highlights its role in precision medicine. The data will be presented at a global oncology meeting in 2025.
Read more →KZIAKazia Therapeutics Announces $2 Million Private Placement at Premium to Market
Kazia Therapeutics has announced a $2 million private placement of equity securities at a 5% premium to the market price. The funds will be used to advance clinical development of its lead programs, including paxalisib and EVT801. The transaction is expected to close on August 4, 2025, pending customary conditions.
Read more →KZIA▲ +39.6%on this news· ran to +67% by day 3
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
Kazia Therapeutics has reported encouraging early efficacy data from its Phase 1b trial of Paxalisib combined with pembrolizumab and chemotherapy. The first patient, a 61-year-old woman with metastatic triple-negative breast cancer, experienced over a 50% reduction in circulating tumor cells after 21 days of treatment. This result is consistent with preclinical studies and suggests a potential for significant clinical benefits.
Read more →KZIA▲ +81.5%on this news
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced...
Kazia Therapeutics has announced promising preclinical data on paxalisib, highlighting its ability to enhance immune response and overcome resistance in triple-negative breast cancer (TNBC). The research indicates that paxalisib, when combined with immune checkpoint inhibitors like KEYTRUDA, shows significant antitumor activity. This study lays the groundwork for a Phase 1b clinical trial aimed at further exploring paxalisib's efficacy in advanced breast cancer.
Read more →KZIA▲ +81.5%on this news
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib s Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) Sydney, Australia 11 June 2025 Kazia Therapeut
Kazia Therapeutics has announced promising preclinical data that supports the potential of its lead drug, paxalisib, in overcoming immunotherapy resistance in triple-negative breast cancer (TNBC). Conducted by Professor Sudha Rao, the study demonstrates how paxalisib can alter the tumor microenvironment, enhancing immune response and synergy with immune checkpoint inhibitors. This finding paves the way for a Phase 1b clinical trial to assess paxalisib's efficacy in advanced breast cancer treatment. The results signify a critical step toward improving therapeutic options for TNBC patients and expanding paxalisib's application beyond brain cancers.
Read more →KZIAKazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2024 Kazia Therapeutics Limited Directors' report 31 December 2024 The directors present their report, together with the financial statements
Kazia Therapeutics Limited's half yearly report for December 31, 2024, indicates a continued focus on pharmaceutical R&D, specifically with their lead program, paxalisib. The company reported a loss of $10.45 million and is facing financial challenges, including a net current liability position. Paxalisib has received various FDA designations but the firm's future operations depend on obtaining necessary funding and navigating current uncertainties in its clinical programs.
Read more →KZIAKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapie
Kazia Therapeutics has announced the dosing of the first patient in its Phase 1b clinical trial for paxalisib in advanced breast cancer. The trial, which aims to evaluate paxalisib in combination with olaparib or pembrolizumab, is designed to assess safety and preliminary efficacy, along with deep biomarker profiling. This study represents a significant step in expanding paxalisib's applications beyond brain cancer to solid tumors, offering potential insights into improving treatment strategies for patients with poor prognoses.
Read more →KZIAKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for...
Kazia Therapeutics has initiated a Phase 1b clinical trial for paxalisib in patients with advanced breast cancer, marking a significant expansion of its application beyond brain cancer. The trial will evaluate paxalisib in combination with olaparib or pembrolizumab, focusing on safety, tolerability, and preliminary efficacy. This study aims to provide insights into the potential of paxalisib to enhance treatment outcomes in solid tumors.
Read more →KZIA▼ -6.5%on this news
May 2025 Kazia Therapeutics Highlights Recent Progress and Provides Business Update Awarded research grant from The Michael J. Fox Foundation for Parkinson s Research (MJFF) to fund research between The Hebrew University
Kazia Therapeutics announced recent advancements in its clinical programs, notably receiving a grant from the Michael J. Fox Foundation for research on paxalisib for Parkinson's disease. The company has initiated a clinical trial evaluating paxalisib in combination with immunotherapy for advanced breast cancer and reached alignment with the FDA on a pivotal phase 3 study design for glioblastoma. Additionally, Kazia raised $3 million in funding during the first quarter of 2025, which includes significant non-dilutive capital.
Read more →KZIA▼ -6.5%on this news
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
Kazia Therapeutics provided a business update highlighting progress in multiple clinical trials, including the launch of studies for paxalisib in treating advanced breast cancer and glioblastoma. The company was awarded a research grant from The Michael J. Fox Foundation to study paxalisib's potential for Parkinson's disease. Additionally, Kazia has raised $3 million in capital during the first quarter of 2025. However, they received a notification from Nasdaq regarding their market value being below the required minimum, necessitating corrective action within a specified timeline.
Read more →KZIA▼ -11%on this news
March 2025 Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the onco
Kazia Therapeutics Limited has announced the sale of its intellectual property and trademark rights for the oncology drug candidate Cantrixil to Vivesto for $1 million. Previously, Vivesto licensed the exclusive rights to develop Cantrixil but has since decided not to pursue it for ovarian cancer and is now focusing on hematological cancers. This sale will provide Kazia with non-dilutive funding to advance its clinical-stage pipeline. Kazia’s lead program, paxalisib, is already under development for multiple forms of brain cancer.
Read more →KZIA▼ -11%on this news
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
Kazia Therapeutics has announced the sale of all intellectual property and trademark rights for its oncology drug candidate, Cantrixil, to Vivesto for USD $1 million. This move comes as Vivesto shifts its focus from ovarian cancer to exploring Cantrixil for hematological cancers. Kazia's CEO expressed satisfaction with the agreement, highlighting the non-dilutive funding it provides for advancing their clinical-stage pipeline. Cantrixil represents a legacy product in Kazia's offerings, and this sale reflects ongoing adjustments in their development strategy.
Read more →KZIAANNUAL REPORT Contents 2 4 6 Chairman and Key About GBM CEO s Letter Milestones 8 12 Environment, Financial Society & Reports Governance ii ASX:KZA | NASDAQ:KZIA Chairman and CEO s The journey of a young biotech Letter c
Kazia Therapeutics has reported significant progress in its Annual Report for the fiscal year ending June 30, 2024, focusing on its drug candidates, paxalisib and EVT-801. The company received Fast Track Designation from the FDA for paxalisib, which is being evaluated across multiple cancer indications. Notably, Kazia delisted from the ASX to focus on the NASDAQ market to better position itself for growth capital. The report highlights promising clinical data and strategic collaborations aimed at advancing therapy options for cancer patients.
Read more →KZIAFebruary 2025 Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson s Disease Sydney
Kazia Therapeutics has been awarded a grant from The Michael J. Fox Foundation to conduct research on the therapeutic potential of paxalisib for Parkinson's disease. This research will be in collaboration with The Hebrew University of Jerusalem, focusing on preclinical studies to explore paxalisib's effects on disease markers and mouse models. Kazia's CEO expressed optimism about the drug's ability to target key pathways related to Parkinson's pathology. The results of this research could inform future therapeutic approaches for treating Parkinson's disease.
Read more →KZIAKazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson
Kazia Therapeutics has received a research grant from The Michael J. Fox Foundation to collaborate with The Hebrew University of Jerusalem on studying paxalisib as a treatment for Parkinson's disease. This grant will fund preclinical studies aimed at understanding the effects of paxalisib on PD-related biomarkers and mouse models. The research focuses on investigating the relationship between the PI3K/AKT/mTORC pathway and the pathology of Parkinson's, building upon previous findings in the field. Kazia's CEO expressed optimism about the collaboration's potential to contribute valuable insights into the disease's treatment.
Read more →KZIA▼ -5.7%on this news
A Diversified Oncology Drug Development Company Kazia Corporate Overview January 2025 NASDAQ: KZIA | X: @KaziaTx Forward Looking Statements This presentation contains forward -looking statements, which can generally be i
Kazia Therapeutics is providing an overview of its oncology drug development pipeline, featuring two investigational drugs, Paxalisib and EVT801, which are focused on significant cancer types including glioblastoma. The company is implementing a licensing-driven business model, sourced from respected pharmaceutical companies, and is actively engaged in clinical trials as well as pursuing regulatory designations to enhance their market position. However, it acknowledges the inherent risks associated with clinical trials and market dynamics which may affect its future success.
Read more →KZIA▲ +37.7%on this newsshared move
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of...
Kazia Therapeutics has announced the launch of a clinical trial evaluating the combination of paxalisib and immunotherapy for advanced breast cancer. The ABC-Pax study is the first of its kind to assess this combination in women with triple-negative breast cancer. The trial aims to enroll 24 patients and will explore the safety and efficacy of this novel treatment approach.
Read more →KZIA▲ +37.7%on this newsshared move
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Sydney; 30 January 2025: Kazia Therapeutics Limited (NASDAQ: KZIA) a
Kazia Therapeutics has announced the regulatory approval and launch of a clinical trial named ABC-Pax, which will evaluate the safety and efficacy of paxalisib in combination with immunotherapy for women with advanced triple-negative breast cancer. This trial is the first of its kind and involves a novel approach to target aggressive cancer types by reinvigorating immune cells. It will enroll 24 patients from various top cancer centers in Queensland, Australia, and includes a cutting-edge liquid biopsy platform for real-time monitoring of treatment response. Kazia’s CEO emphasized the potential of this combination therapy to significantly impact patient outcomes in an area of high medical need.
Read more →KZIAKazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Kazia Therapeutics has announced the successful closure of a $2.0 million registered direct offering with Alumni Capital LP. This transaction involves the sale of 1,333,333 American Depositary Shares at a price of $1.50 each, along with unregistered warrants for additional ADSs. The funds will be allocated towards general corporate uses, including research and clinical development. The offering was facilitated by Maxim Group LLC.
Read more →KZIA▼ -6.5%on this newsshared move
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
Kazia Therapeutics Limited has announced a registered direct offering to raise $2.0 million by selling 1,333,333 American Depositary Shares at $1.50 each. The company plans to use the proceeds for general corporate purposes, including research and clinical development. The offering is expected to close around January 13, 2025, pending customary conditions.
Read more →KZIA▼ -6.5%on this newsshared move
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
Kazia Therapeutics Limited has announced a registered direct offering to raise up to $2.0 million through the sale of American Depositary Shares. Each share will be priced at $1.50, with unregistered warrants also being issued in a concurrent private placement. The company plans to use the proceeds for various corporate purposes, including research and clinical development expenses. The offering's closing is anticipated on or about January 13, 2025, pending customary closing conditions.
Read more →KZIA▼ -42.9%on this news
December 2024 Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA Sydney
Kazia Therapeutics provided a regulatory update on paxalisib for glioblastoma following a Type C meeting with the FDA. The agency indicated that while the overall survival data from the GBM-AGILE study is supportive, it does not suffice for accelerated approval; however, it can inform a standard approval pathway. Kazia has aligned with the FDA on critical aspects for a pivotal Phase 3 study design. The company is also exploring other treatment indications and presented promising data on paxalisib's efficacy in combination therapies.
Read more →KZIA▼ -42.9%on this news
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Kazia Therapeutics provided an update on its regulatory pathway for paxalisib after a Type C meeting with the FDA. While the FDA indicated that the current overall survival data from the GBM-AGILE study is not sufficient for accelerated approval, it supports a traditional approval route and has aided in designing a pivotal phase 3 study. The company is also exploring additional indications for paxalisib and has received designations for pediatric conditions. Upcoming plans for maximizing shareholder value will be shared by the end of January 2025.
Read more →KZIADecember 2024 Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Sympo
Kazia Therapeutics announced that it will present data at the San Antonio Breast Cancer Symposium regarding its lead product candidate, paxalisib, highlighting its potential effectiveness in treating immunotherapy-resistant triple negative breast cancer and HER2 positive metastatic breast cancer with brain metastases. The data indicates synergistic effects when paxalisib is combined with existing therapies like pembrolizumab and olaparib. Despite not meeting the primary endpoint of overall response rate in one trial, paxalisib showed encouraging overall survival rates in a heavily pretreated patient population. Ongoing work aims to further explore the mechanisms involved and translate findings into clinical development.
Read more →KZIAKazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium
Kazia Therapeutics will present data at the San Antonio Breast Cancer Symposium showcasing the potential of paxalisib in combination with checkpoint inhibitors and other therapies for treating immunotherapy-resistant triple negative breast cancer. The findings indicate synergistic effects that may improve treatment outcomes for patients who have not responded to standard therapies. However, while preclinical results are promising, clinical trials demonstrated that primary endpoints were not met, pointing to challenges in translating findings into effective treatments.
Read more →KZIA▲ +19.2%on this news
November 2024 Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Company and FDA to meet in December
Kazia Therapeutics Limited announced that the FDA has granted a Type C meeting to discuss potential registration pathways for paxalisib, aimed at treating newly diagnosed glioblastoma multiforme. The meeting is scheduled for December 2024. This follows positive results from the Phase II/III GBM-AGILE clinical trial, which indicated significant survival benefits for patients treated with paxalisib. Additionally, Kazia has updated its corporate presentation to include this new data and plans to engage with key stakeholders at upcoming medical conferences.
Read more →KZIA▲ +19.2%on this news
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
Kazia Therapeutics Limited announced that the FDA has granted a Type C meeting to discuss potential registration pathways for its drug paxalisib, aimed at treating newly diagnosed glioblastoma multiforme (GBM). The meeting is scheduled for December 2024 following positive results from the GBM-AGILE Phase II/III clinical trial, which demonstrated meaningful improvements in overall survival. Kazia also updates its corporate presentation with preliminary trial data and outlines participation in various upcoming medical conferences to engage stakeholders and promote its therapeutic innovations.
Read more →KZIAOctober 2024 Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring
Kazia Therapeutics has announced promising Phase I data evaluating the combination of paxalisib and radiation therapy for patients with solid tumor brain metastases harboring PI3K pathway mutations. The study presented a 67% partial response rate, indicating a favorable outcome when compared to traditional whole brain radiation therapy. Further data, including ctDNA results, is expected at an upcoming scientific congress, while discussions on a pivotal registration study for this combination therapy are ongoing. The results highlight the potential of paxalisib in addressing tumor radioresistance.
Read more →KZIAKazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
Kazia Therapeutics announced promising Phase I data on their investigational drug paxalisib, combined with radiation therapy for solid tumor brain metastases with PI3K pathway mutations. The study reported a 67% partial response rate among patients treated at a maximum tolerated dose. The results were presented at the American Society for Radiation Oncology Annual Meeting, highlighting improved intracranial response rates compared to traditional therapies. Ongoing discussions for further pivotal studies and additional data analysis are anticipated.
Read more →KZIASeptember 2024 Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15 th Biennial Ovarian Cancer Research Symposium Sydney
Kazia Therapeutics has announced the presentation of promising clinical data for EVT801 during the 15th Biennial Ovarian Cancer Research Symposium. The Phase 1 trial evaluated the safety and tolerability of EVT801, a VEGFR3 inhibitor, and successfully identified a maximum tolerated dose. Dr. John Friend, CEO of Kazia, highlighted the encouraging nature of the trial results, presenting the potential for EVT801 to be a first-in-class option for patients with high grade serous ovarian cancer. These findings contribute to Kazia's ongoing research efforts in oncology.
Read more →KZIAKazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Kazia Therapeutics presented promising preliminary data on EVT801, a VEGFR3 inhibitor, at the 15th Biennial Ovarian Cancer Research Symposium. The Phase 1 trial showed that EVT801 was well-tolerated, achieving its primary objectives, and demonstrated clinical activity, particularly in patients with high-grade serous ovarian cancer. Key findings included a 46% stable disease rate in advanced ovarian cancer patients and a noted partial response in one patient. The recommended Phase 2 dose was identified as 400mg twice daily.
Read more →KZIA▼ -5.3%on this news
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
Kazia Therapeutics Limited has executed an exclusive licensing agreement with QIMR Berghofer Medical Research Institute to develop combination therapies involving PI3K inhibitors and immunotherapies or PARP inhibitors. This agreement builds on a successful collaboration that began in December 2022, supporting the development of Kazia's lead candidate, paxalisib, particularly for treating breast cancer. The license includes provisions for an upfront fee and milestone payments linked to clinical trials. Key insights from preclinical studies indicate paxalisib's potential to enhance the efficacy of immunotherapies in combatting cancer.
Read more →KZIA▼ -5.3%on this news
September 2024 KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER Sydney
Kazia Therapeutics Limited has executed a licensing agreement with QIMR Berghofer Medical Research Institute for exclusive rights to develop combination therapies involving PI3K inhibitors and immunotherapies. This agreement, stemming from a successful collaboration since December 2022, allows Kazia to advance its lead candidate, paxalisib, in treating various solid tumors. The terms of the agreement include an upfront fee and development milestones linked to clinical trial phases. Kazia's past research has shown promising results in preclinical studies involving paxalisib combined with other cancer treatments.
Read more →KZIA▲ +248%on this news· ran to +546% by day 1
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase...
Kazia Therapeutics announced positive results from the GBM-AGILE Phase II/III trial, showing a 3.8 month improvement in overall survival for newly diagnosed unmethylated glioblastoma patients treated with paxalisib compared to standard care. The trial involved 313 patients and demonstrated significant outcomes in survival metrics. Kazia plans to discuss potential accelerated approval pathways with the FDA based on these findings.
Read more →KZIA▲ +248%on this news· ran to +546% by day 1
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in pax
Kazia Therapeutics announced positive Phase II/III trial results for paxalisib in treating glioblastoma, showing a 3.8 month increase in overall survival compared to standard care. The trial, part of the GBM AGILE study, highlighted significant benefits for newly diagnosed unmethylated patients. The company plans to discuss possible accelerated approval with the FDA based on these promising outcomes. Further detailed results from the trial are expected to be presented at a scientific meeting later in 2024.
Read more →KZIA▲ +6.4%on this news
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
Kazia Therapeutics Limited announced its upcoming presentations of new data regarding its lead program, paxalisib, at the ISPNO 2024 conference. Three presentations will focus on the efficacy of paxalisib in treating Diffuse Midline Glioma (DMG) and the combination therapies involving other agents. Concurrently, an article has been published in the European Journal of Cancer, highlighting the demand for mutation-specific treatments in pediatric oncology. These developments showcase Kazia’s commitment to advancing therapeutic options for children dealing with severe forms of brain cancer.
Read more →KZIAKazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
Kazia Therapeutics Limited has been granted an additional 180 days by Nasdaq to meet the Minimum Bid Price Requirement after not regaining compliance by the initial deadline. The company maintains that their stocks will continue to trade normally while they monitor their bid price. Kazia has plans to address the deficiency and may consider changing the ratio of their American Depositary Shares if necessary. There is a possibility of delisting if compliance is not achieved, but Kazia can appeal any determinations made by Nasdaq.
Read more →KZIA▼ -10.8%on this news
May 2024 KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS Sydney
Kazia Therapeutics announced the successful completion of Stage 1 in its Phase 1 clinical trial of EVT801 for advanced cancer patients. The Safety Review Team confirmed that both primary and secondary objectives were met, establishing a maximum tolerated dose of 500mg BID and a recommended phase 2 dose of 400mg BID. Notably, nearly half of the advanced ovarian cancer patients exhibited stable disease after treatment. With promising results, Kazia plans to present more detailed data at a scientific conference later this year.
Read more →KZIA▼ -10.8%on this news
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
Kazia Therapeutics Limited has announced the successful completion of Stage 1 of the EVT801 Phase 1 clinical trial aimed at treating advanced cancer patients. The Safety Review Team confirmed that the trial met all primary and secondary objectives and identified a maximum tolerated dose of EVT801. Preliminary data suggests that EVT801 is well tolerated and shows potential clinical activity, particularly among patients with advanced ovarian cancer. Kazia plans to present the final Stage 1 data at a scientific conference later in 2024.
Read more →KZIAKazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2023 Kazia Therapeutics Limited Directors' report 31 December 2023 The directors present their report, together with the financial statements
Kazia Therapeutics Limited released its Half Yearly Report for the period ending 31 December 2023, detailing financial performance and operational updates. The company reported a loss of $8.8 million, a decrease from the previous year's $13.6 million loss, and highlighted its lack of revenue generation. Key developments include ongoing research activities related to its lead drug, paxalisib, which has received multiple FDA designations aimed at improving treatment outcomes for glioblastoma. Despite the challenges, the company is actively seeking additional funding sources to support its operations and continues to advance its clinical trials.
Read more →KZIA▼ -8.9%on this news
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
Kazia Therapeutics has entered into an exclusive licensing agreement with Sovargen Co., Ltd. for the development and commercialization of paxalisib, aimed at treating intractable epilepsy in focal cortical dysplasia type 2 and tuberous sclerosis complex. The agreement includes an upfront payment of $1.5 million and additional milestone payments based on development achievements. This collaboration seeks to address the significant unmet medical needs of patients suffering from these rare conditions, as paxalisib has shown promise in targeting the PI3K/Akt/mTOR pathway.
Read more →KZIA▼ -8.9%on this news
March 2024 Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases Sydney
Kazia Therapeutics has entered an exclusive agreement with Sovargen to license paxalisib for treating intractable seizures associated with rare CNS diseases, specifically focal cortical dysplasia type 2 and tuberous sclerosis complex. The agreement includes an upfront payment of $1.5 million and potential milestone payments totaling up to $19 million. Kazia retains rights in Mainland China, Hong Kong, Macao, and Taiwan. The dual inhibition mechanism of paxalisib is expected to initiate a Phase 2 clinical trial for these conditions later in 2024, addressing significant unmet medical needs.
Read more →KZIA▲ +8.4%on this news
Kazia announces presentation of new data at AACR Annual Meeting
Kazia Therapeutics Limited announced the upcoming presentation of new data for its pipeline molecules, paxalisib and EVT801, at the AACR Annual Meeting from April 5-10, 2024. The presentations will include findings from the phase 1 study of EVT801 in advanced solid cancers, as well as combination therapy results for paxalisib and gemcitabine for atypical teratoid/rhabdoid tumors. The Pacific Pediatric Neuro-Oncology Consortium plans to include this therapy in its next international clinical trial, indicating positive progress in Kazia's research efforts.
Read more →KZIA▼ -20.6%on this news
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
Kazia Therapeutics announced the early conclusion of a Phase I trial evaluating paxalisib combined with radiation therapy for brain metastases with PI3K pathway mutations. The trial demonstrated positive safety and promising clinical efficacy in initial patient cohorts. Kazia's CEO expressed enthusiasm about the results and the firm's plans to engage with the FDA to discuss future pivotal studies. The findings will also be presented at an upcoming scientific meeting, contributing to the dialogue regarding new treatment options for complex brain metastases.
Read more →KZIA▼ -20.6%on this news
February 2024 Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint Paxalisib plus Radiotherapy Data Shows Promise for Treating Patients with PI3K Pathway Mutation Brain Metastases
Kazia Therapeutics announced the early conclusion of a Phase I trial for paxalisib, which combines an oral PI3K/mTOR inhibitor with radiation therapy for treating patients with brain metastases harboring PI3K pathway mutations. The trial achieved its primary endpoint, demonstrating promising efficacy and safety in patients. The company is preparing to consult with the FDA for guidance on progressing towards a pivotal registration study. Findings from the trial will be presented at an upcoming scientific meeting to discuss treatment options for this patient demographic.
Read more →KZIAKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
Kazia Therapeutics Limited announced the addition of Robert Apple to its Board of Directors as a Non-Executive Director, bringing extensive pharma experience. Mr. Bryce Carmine has been appointed Chairman, furthering the board renewal process. The CEO of Kazia highlighted the valuable expertise of the new leadership for the company’s next growth phase. Kazia continues to develop its lead oncology program, paxalisib, targeting various forms of brain cancer.
Read more →KZIAJanuary 2024 KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS 18 January 2024 Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the ap
Kazia Therapeutics Limited announced the appointment of Robert Apple as a Non-Executive Director and Bryce Carmine as the new Chairman of the Board. Apple brings over 25 years of experience in the pharma industry, enhancing the Board's leadership capabilities. Kazia's CEO highlighted the significance of this leadership renewal as the company prepares for growth. Additionally, the company is progressing with its lead program, paxalisib, which targets multiple brain cancer forms and has reported encouraging clinical data.
Read more →KZIAKazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
Kazia Therapeutics Limited has announced the completion of a $2 million registered direct offering of American Depositary Shares (ADSs). The offering involved the sale of 4,444,445 ADSs at a price of $0.45 each and included the issuance of unregistered warrants. The net proceeds from the offering will be utilized for working capital and corporate initiatives. Kazia continues to develop its lead program, paxalisib, for various forms of brain cancer, with ongoing clinical trials providing positive interim data.
Read more →KZIAKazia Therapeutics Announces Closing of $2 Million Registered Direct Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced the closing of...
Kazia Therapeutics has successfully closed a $2 million registered direct offering, selling 4,444,445 American Depositary Shares at $0.45 each. The proceeds will be used for general corporate purposes. The company is focused on developing its lead program, paxalisib, for treating various brain cancers, with ongoing clinical trials showing encouraging results.
Read more →KZIA▼ -19.6%on this newsshared move
Kazia Therapeutics Announces $2 Million Registered Direct Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has...
Kazia Therapeutics has announced a registered direct offering to raise approximately $2 million by selling 4,444,445 American Depositary Shares at $0.45 each. The company plans to use the proceeds for general corporate purposes. The offering is expected to close around December 5, 2023, pending customary conditions. Kazia is focused on developing treatments for various forms of brain cancer, with its lead program, paxalisib, showing promising results in clinical trials.
Read more →KZIA▼ -19.6%on this newsshared move
Kazia Therapeutics Announces $2 Million Registered Direct Offering
Kazia Therapeutics has announced a registered direct offering of up to 4,444,445 American Depositary Shares (ADSs) at $0.45 per share, with expected gross proceeds of $2 million. Concurrently, unregistered warrants to purchase additional ADSs will be issued, further expanding their capital raise. The company plans to use the proceeds for working capital. The offering is scheduled to close on or about December 5, 2023, contingent on customary closing conditions.
Read more →KZIA▼ -6.3%on this news· ran to -30% by day 3shared move
November 2023 KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY 29 November 2023 Kazia Therapeutics Limited (NASD
Kazia Therapeutics has signed a non-binding Letter of Intent (LOI) with an undisclosed biotechnology company for the worldwide rights to develop and commercialize paxalisib outside of oncology. Both parties completed mutual due diligence and are negotiating a definitive license agreement, which includes various payment structures. However, the completion of this agreement is not guaranteed, leaving the timeline and conditions uncertain.
Read more →KZIA▼ -6.3%on this news· ran to -30% by day 3shared move
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
Kazia Therapeutics Limited has signed a non-binding Letter of Intent with an undisclosed biotechnology company to potentially develop and commercialize paxalisib outside of oncology. The LOI outlines proposed terms and conditions, including a 90-day exclusivity period for negotiations. While mutual due diligence has been completed, there is no assurance a definitive agreement will be reached, and the companies are currently discussing the specifics of the license agreement. The CEO highlighted that this alliance could leverage strengths to address significant unmet medical needs in other indications.
Read more →KZIA▼ -6.3%on this news· ran to -30% by day 3shared move
KAZIA THERAPEUTICS LIMITED ABN 37 063 259 754 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. THE MATTERS RAISED IN THIS DOCUMENT WILL AFFECT YOUR SHAREHOLDING IN THE COMPANY. YOU ARE ADVISED TO READ TH
Kazia Therapeutics Limited is convening its 2023 Annual General Meeting (AGM) online on November 30, 2023, affecting shareholder engagement. The company has formally requested to delist from the Australian Securities Exchange (ASX), with the last trading day set for November 13, 2023. This move is attributed to the costs and challenges associated with remaining listed on the ASX, and the company will continue to trade its American Depositary Shares (ADSs) on NASDAQ. Shareholders are urged to vote online and participate actively in the upcoming AGM.
Read more →KZIA▼ -10.6%on this news· ran to -23% by day 3
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
Kazia Therapeutics Limited provided key highlights from the Society of Neuro-Oncology 2023 Annual Meeting, focusing on presentations related to their drug paxalisib. The company reported promising preliminary overall survival data from the PNOC022 clinical study, which explores tailored treatments for CNS malignancies. Innovative combination therapies were presented, showing statistically significant improvements in treatment outcomes for diffuse midline glioma. The meeting showcased collaboration among leading researchers and the ongoing commitment to enhancing clinical strategies for treating brain cancer.
Read more →KZIA▼ -10.6%on this news· ran to -23% by day 3
November 2023 KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING 21 November 2023 Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-foc
Kazia Therapeutics Limited (NASDAQ: KZIA) announced key highlights from the Society of Neuro-Oncology 2023 Annual Meeting, focusing on advancements in treatments for central nervous system malignancies using its lead drug, paxalisib. CEO Dr. John Friend expressed optimism regarding preliminary survival data from the PNOC022 clinical study. Presentations included promising results on combination therapies targeting diffuse midline glioma and the genetic factors influencing treatment efficacy. Kazia aims to leverage these insights to enhance therapeutic options and improve patient outcomes in brain cancer.
Read more →KZIA▼ -6.1%on this newsshared move
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION Sydney
Kazia Therapeutics Limited has received a deficiency notification from Nasdaq for failing to meet the minimum bid price requirement for continued listing. This notification does not impact the company's operations as its securities will continue to trade normally. Kazia has been given 180 calendar days to regain compliance, with the possibility of a further extension if necessary. The company's lead program, paxalisib, is currently undergoing several clinical trials which have shown promising data.
Read more →KZIA▼ -6.1%on this newsshared move
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a deficiency notification from the Listing Qualifications Staff of the...
Kazia Therapeutics Limited received a notification from Nasdaq regarding non-compliance with minimum bid price requirements. The company has 180 days to regain compliance, during which its securities will continue to trade normally. Kazia is actively monitoring the situation and has ongoing clinical trials that may positively influence its market position.
Read more →KZIANovember 2023 KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING 15 Novemb
Kazia Therapeutics has announced the release of a clinical study abstract highlighting its investigational drug paxalisib for diffuse midline glioma patients. The early results indicate a median overall survival of 16.5 months, which is significantly better than the standard care's average of about 8-11 months. The study, PNOC022, uses a combination therapy approach and involves children's cancer centers worldwide. Further data from additional cohorts is expected in 2024.
Read more →KZIAKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
Kazia Therapeutics has announced the release of a clinical study abstract for its investigational drug, paxalisib, for patients with diffuse midline gliomas (DMGs) at the Society of Neuro-Oncology 2023 Annual Meeting. The abstract reports a median overall survival of 16.5 months for patients treated in a study comprising 68 children and young adults. Results are anticipated to be presented in further detail at the conference on November 19, 2023. Kazia’s collaboration with a wide network of cancer centers underscores its commitment to addressing pediatric brain tumors with innovative therapies.
Read more →KZIA▲ +12.5%on this news· ran to +25% by day 3shared move
November 2023 KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA Sydney, 10 November 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA)
Kazia Therapeutics announced the publication of preclinical data on paxalisib in the journal Molecular Cancer Therapeutics. The research, conducted in collaboration with the Huntsman Cancer Institute, indicates that paxalisib effectively targets metastatic melanoma, a severe form of skin cancer. The findings suggest that paxalisib could serve as a therapeutic option for BRAF-mutant melanoma, especially in cases resistant to MAPK inhibitors. The company plans to evaluate future clinical trial opportunities for paxalisib in melanoma based on upcoming results in 2024.
Read more →KZIAKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
Kazia Therapeutics has published promising preclinical data on paxalisib, demonstrating its effectiveness against metastatic melanoma, including in models resistant to existing therapies. The research, conducted in collaboration with the Huntsman Cancer Institute, shows that paxalisib inhibits tumor growth and extends survival rates in preclinical studies. This represents a potential therapeutic strategy for BRAF-mutant cutaneous melanoma. Kazia anticipates further developments and potential clinical trials in this area in the near future.
Read more →KZIAASX RELEASE 01 Nov 2023 KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA Sydney, 01 Nov 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-
Kazia Therapeutics has provided a preliminary update from its ongoing Phase 2 study of paxalisib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL). The open-label trial is evaluating paxalisib as a monotherapy, and to date, 14 patients have been enrolled. Preliminary clinical activity has been observed, but some patients have faced treatment-related adverse events resulting in changes to the dosing protocol. The study aims to further assess the efficacy and safety of paxalisib in this challenging condition.
Read more →KZIAKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
Kazia Therapeutics has provided a preliminary update from its ongoing Phase 2 study of paxalisib for patients with relapsed/refractory primary central nervous system lymphoma. Fourteen patients have been enrolled, with some demonstrating partial responses and stable disease. However, treatment-related adverse events led to dose reductions and early terminations for some participants. In response, the dosing regimen is being optimized to enhance tolerability and clinical benefits. More updates are anticipated as the study progresses.
Read more →KZIA▼ -5.3%on this news
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
Kazia Therapeutics presented selected clinical data from its ongoing Phase 1 trial of EVT801 at ESMO 2023. The data included a correlation analysis from patients with advanced high-grade serous ovarian cancer (HGS-OC), indicating potential associations between VEGFR3 expression and various tumor-related factors. The company aims to complete dose escalation in the ongoing study, which could pave the way for further stages of clinical evaluation. These findings underscore Kazia's commitment to advancing treatment options in oncology despite challenges in the field.
Read more →KZIA▼ -5.3%on this news
ASX RELEASE 23 Oct 2023 KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY Sydney, 23 Oct 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug developm
Kazia Therapeutics has reported clinical data from its Phase 1 trial of EVT801, presented at the ESMO 2023 conference. This trial targets patients with advanced solid tumors, particularly high grade serous ovarian cancer. Data presented indicates a positive correlation between VEGFR-3 expression and treatment resistance, highlighting potential avenues for overcoming challenges in ovarian cancer treatment. The company looks forward to advancing to stage 2 of the trial following the completion of dose escalation in stage 1.
Read more →KZIA▼ -8.7%on this news
ASX RELEASE 13 October 2023 SHAREHOLDER COMMUNICATION ON THE DE-LISTING PROCESS Sydney, 13 October 2023 Kazia Therapeutics Limited ( Kazia or the Company ) NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development co
Kazia Therapeutics Limited has announced its voluntary delisting from the Australian Securities Exchange (ASX). The decision, effective from November 15, 2023, follows a notification sent to shareholders on October 11, 2023. Important associated dates include the last trading day for shares on ASX on November 13, 2023, and the closure of the ADS Conversion Facility on the same day. This move could impact investor confidence and the company’s visibility in the market.
Read more →KZIA▼ -15.8%on this news· ran to -27% by day 3shared move
ASX RELEASE 11 October 2023 KAZIA ANNOUNCES VOLUNTARY DELISTING FROM ASX Sydney, 11 October 2023 - Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) ( Kazia or the Company ), an oncology-focused drug development company,
Kazia Therapeutics Limited announced its intention to voluntarily delist from the Australian Securities Exchange (ASX). The company has submitted a formal application for this delisting, citing costs and administrative burdens as key considerations. While it will maintain its listing on NASDAQ, shareholders need to be aware of how they can sell their shares post-delist. The Board emphasizes that the change is in the best interest of the company and its shareholders.
Read more →KZIA▼ -15.8%on this news· ran to -27% by day 3shared move
Kazia announces voluntary delisting from ASX
Kazia Therapeutics Limited has announced its intention to voluntarily delist from the Australian Securities Exchange (ASX) while maintaining its listing on NASDAQ. This decision aims to minimize costs and administrative burdens associated with the dual listing, as the company believes that a single listing on NASDAQ will provide better access to capital from a market more familiar with biotechnology. Consequently, shareholders will need to adjust to trading their shares exclusively on NASDAQ following the delisting. Kazia has indicated it will notify shareholders regarding the specifics of the delisting process and what it entails for them.
Read more →KZIA▼ -15.8%on this news· ran to -27% by day 3shared move
Market Announcement 10 October 2023 Kazia Therapeutics Limited (ASX: KZA) Suspension from Quotation Description The securities of Kazia Therapeutics Limited ( KZA ) will be suspended from quotation immediately under List
Kazia Therapeutics Limited (KZA) has requested a voluntary suspension of its securities on the Australian Securities Exchange (ASX) under Listing Rule 17.2. This suspension is in advance of an announcement regarding its proposed transition to trading solely on Nasdaq and potential delisting from the ASX. The company is currently focused on its lead drug, paxalisib, which is still undergoing clinical trials. This move reflects a significant strategy shift for Kazia, potentially impacting its investor base and market presence.
Read more →KZIA▼ -15.8%on this news· ran to -27% by day 3shared move
October 2023 Ms Lisa Bahn Senior Adviser, Listings Compliance ASX Limited, 20 Bridge Street SYDNEY NSW 2000 REQUEST FOR TRADING HALT BY EMAIL: tradinghaltssydney@asx.com.au Dear Lisa Kazia Therapeutics Limited- Request f
Kazia Therapeutics Limited has submitted a request for an immediate trading halt on the Australian Securities Exchange, citing compliance with ASX Listing Rule 17.1. The company is well-known for its oncology drug, paxalisib, which has shown positive clinical data in trials for brain cancer. Kazia also develops EVT801, a new candidate with promising preclinical results. The announcement underscores ongoing risks and uncertainties related to clinical trials and market conditions.
Read more →KZIAKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS
Kazia Therapeutics Limited has announced upcoming presentations of its investigational drugs, EVT801 and Paxalisib, at the ESMO Congress 2023 and SNO Annual Meeting. The presentations will provide insights into new data supporting the clinical efficacy and usage of these agents in fighting various forms of brain cancer. Notably, Paxalisib has been granted multiple FDA designations, enhancing its development capabilities as the company continues to push forward with its oncology-focused pipeline.
Read more →KZIA▼ -5.2%on this news
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Kazia Therapeutics has announced the acceptance of a late-breaking abstract for an oral presentation concerning clinical data from its Phase II study of paxalisib at the 2023 Society for Neuro-Oncology Annual Meeting. The PNOC022 study, which targets diffuse intrinsic pontine glioma and other midline gliomas, is part of an ongoing effort at increasing understanding and treatment options for these challenging brain tumors. The conference will take place in Vancouver from November 15-19, 2023, where Kazia's findings will be presented to an audience of industry experts and stakeholders.
Read more →KZIA▼ -5.2%on this news
ASX RELEASE 29 September 2023 KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING Sydney, 29 September 2023 K
Kazia Therapeutics Limited announced the acceptance of a late-breaking abstract and oral presentation of clinical data from its PNOC022 trial at the 2023 Society for Neuro-Oncology Annual Meeting. The PNOC022 study is focused on paxalisib, an investigational drug for diffuse intrinsic pontine glioma and similar diseases. The presentation is significant due to the prestige associated with the Society for Neuro-Oncology and could enhance visibility for Kazia's research efforts. The meeting will take place in Vancouver, Canada from November 15-19, 2023.
Read more →KZIAANNUAL REPORT 2023 CONTENTS CHAIRMAN AND CEO S LETTER KEY MILESTONES INTRODUCTION TO KAZIA S CEO PIPELINE REVIEW ENVIRONMENT, SOCIETY & GOVERNANCE FINANCIAL REPORTS 2 6 8 10 12 14 ii ASX:KZA | NASDAQ:KZIA The past year h
Kazia Therapeutics has reported a significant year of progress, notably in its clinical programs for paxalisib, focusing on adult brain cancer, pediatric brain cancer, and brain metastases. The drug received Fast Track Designation from the FDA, enhancing its development momentum. The company has also reached milestones in its clinical trials, including promising data from ongoing studies. Furthermore, Kazia has secured new funding to support its advancement in these programs, indicating strong potential moving forward.
Read more →KZIAASX RELEASE 11 August 2023 KAZIA THERAPEUTICS ANNOUNCES CHANGE TO BOARD OF DIRECTORS Sydney, 11 August 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced the
Kazia Therapeutics announced the resignation of Chairman Iain Ross, effective immediately, with Dr. John Friend taking over as Interim Chairman. Ross's leadership over the past eight years has been lauded for positioning the company for success. Kazia remains focused on advancing its oncology programs, specifically with its lead product, paxalisib, which is undergoing various clinical trials. The company acknowledges potential risks stemming from the leadership change and ongoing clinical development.
Read more →KZIA▼ -8.5%on this news
KAZIA S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY Sydney, 06 JULY 2023 Kazia Therapeutics Limi
Kazia Therapeutics has announced that its investigational drug, paxalisib, has been granted Fast Track Designation by the FDA for the treatment of solid tumor brain metastases with PI3K pathway mutations when combined with radiation therapy. This designation was based on promising clinical data from an ongoing Phase 1 trial, where all evaluable patients showed clinical responses to the treatment combination. Kazia aims to advance its research in brain cancer, with several important data readouts scheduled for later in 2023.
Read more →KZIAASX ANNOUNCEMENT 26 June 2023 KAZIA CORPORATE UPDATE AND CORPORATE PRESENTATION Sydney, 26 June 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provid
Kazia Therapeutics Limited provided a corporate update highlighting key initiatives and clinical programs as it transitions to the second half of 2023. New CEO Dr. John Friend emphasized confidence in the company's pipeline, particularly with paxalisib, which has ongoing studies for various brain cancers including pivotal trials. Kazia anticipates critical data from its clinical trials and plans to keep investors informed of any significant progress.
Read more →KZIAKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
Kazia Therapeutics has announced a phase II clinical study, LUMOS2, to evaluate paxalisib for adult patients with recurrent IDH-mutant grade 2 and 3 gliomas. The study will be conducted by the University of Sydney and aims to address significant unmet medical needs in this patient population. It is expected to enroll up to 76 patients at multiple Australian sites and possibly expand internationally. This initiative builds on previous positive data from trials involving paxalisib and aims to enhance treatment options for these challenging brain cancers.
Read more →KZIAASX ANNOUNCEMENT 5 June 2023 KAZIA EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF EBRU DAVIDSON Ms Ebru Davidson appointed as a Non-Executive Director Sydney, 5 th June 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX:
Kazia Therapeutics Limited has appointed Ebru Davidson as a Non-Executive Director as part of its Board renewal strategy. This appointment aims to strengthen governance and offers extensive expertise in corporate legal strategy and compliance. Davidson has a strong background in equity capital markets and corporate transactions, vital for the company’s ongoing initiatives in oncology-focused drug development.
Read more →KZIAKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE CANCER MOONSHOT
Kazia Therapeutics Limited has been invited to participate in the White House Cancer Moonshot Brain Cancers Forum focused on glioblastoma and diffuse intrinsic pontine glioma, highlighting its role in developing treatments for these aggressive cancers. CEO Dr. John Friend will represent the company at the event, which aims to gather experts and stakeholders to discuss innovative strategies for improving patient outcomes. This invitation underscores Kazia's commitment to tackling rare brain cancers and reinforces its reputation in the oncology field.
Read more →KZIAASX ANNOUNCEMENT 1 st May 2023 KAZIA ANNOUNCES EXECUTIVE LEADERSHIP CHANGES Dr John Friend appointed Chief Executive Officer, succeeding Dr James Garner Sydney, 1 st May 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX
Kazia Therapeutics Limited has announced the resignation of its CEO Dr James Garner, effective immediately, with Dr John Friend taking over as CEO. Dr Garner has played a pivotal role in transforming Kazia and has contributed to significant advancements, including the clinical programs involving paxalisib and EVT801. The Board expresses gratitude for his leadership as the company prepares for upcoming clinical outcomes. Dr Friend, previously the Chief Medical Officer, is expected to steer the company into its next growth phase.
Read more →KZIA▲ +9.1%on this news· ran to +25% by day 3
KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Kazia Therapeutics Limited has successfully regained compliance with Nasdaq's minimum bid price requirement, as the company’s American Depository Shares closed above $1.00 for ten consecutive business days. Previously, the company was notified of a deficiency due to its ADSs trading below the required price. The notification confirms that Kazia remains a compliant entity on the Nasdaq stock market, allowing sustained trading of its shares. The company continues to advance its oncology drug development programs, notably with paxalisib for brain cancer.
Read more →KZIA▲ +9.1%on this news· ran to +25% by day 3
ASX ANNOUNCEMENT 14 April 2023 KAZIA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT Sydney, 14 April 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, i
Kazia Therapeutics Limited has regained compliance with Nasdaq's minimum bid price requirement, having met the criteria within the stipulated time frame. This notification confirms that the company's American Depository Shares (ADSs) have closed above the $1.00 mark for ten consecutive business days. Kazia has multiple ongoing clinical trials aimed at treating various forms of brain cancer with its lead compound, paxalisib. The company continues to advance its drug development programs with supportive interim data from these trials.
Read more →KZIA▲ +6.9%on this news
KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING
Kazia Therapeutics announced the presentation of new data on its oncology pipeline molecules, paxalisib and EVT801, at the upcoming AACR Annual Meeting. The findings highlight the effectiveness of paxalisib in melanoma and childhood brain cancer, showcasing evidence of increased survival rates in mouse models. Additionally, the collaboration with Evotec indicates a promising direction for identifying responsive patient populations in clinical studies. Five abstracts will be presented, including critical data on combination therapies.
Read more →KZIA▲ +6.9%on this news
ASX ANNOUNCEMENT 4 April 2023 KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING Sydney, 4 April 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company
Kazia Therapeutics Limited announced it will present new data for its drugs paxalisib and EVT801 at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. The presentations, which build on previous positive data about paxalisib's effectiveness in melanoma and childhood brain cancer, will provide critical insights for future development. Kazia's collaboration with Evotec on EVT801 is expected to yield initial clinical data in 2023. This showcases the ongoing progress and potential of Kazia's oncology pipeline, particularly with the emphasis on biomarker strategies, which might enhance approval chances from the FDA.
Read more →KZIAKazia Therapeutics Limited Appendix 4D Half-year report 1. Company details Name of entity: Kazia Therapeutics Limited ABN: 37 063 259 754 Reporting period: For the half-year ended 31 December 2022 Previous period: For th
Kazia Therapeutics Limited reported a loss of $13.586 million for the half-year ending December 31, 2022, reflecting a 2.9% increase from the previous year. The company has no operating revenue, with total operating expenses rising significantly to $4.276 million. Despite these financial challenges, Kazia is actively engaged in research and development, particularly with its lead drug candidate, paxalisib, which is undergoing multiple clinical trials and has shown potential efficacy in glioblastoma treatment.
Read more →KZIAASX ANNOUNCEMENT 7 March 2023 KAZIA THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION FOR AUSTRALIAN PHASE II PRECISION MEDICINE STUDY OF PAXALISIB IN CHILDHOOD CANCERS Sydney, 7 March 2023 Kazia Therapeutics Limited (NASDAQ
Kazia Therapeutics has announced a collaboration with the Australian and New Zealand Children’s Haematology/Oncology Group for a Phase II clinical study named OPTIMISE. This study will evaluate paxalisib in children with advanced solid tumors, particularly focusing on those with specific genetic mutations. The initiative aims to harness learnings from the Zero Childhood Cancer Program to provide tailored therapies for pediatric patients. Enrollment for the study is expected to begin in the second half of 2023, initially in Australia but possibly expanding internationally in the future.
Read more →KZIAASX ANNOUNCEMENT 24 February 2023 RESULTS OF EGM Sydney, 24 February 2023 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the results of the EGM h
Kazia Therapeutics Limited announced the successful outcomes of its Extraordinary General Meeting (EGM) held on February 24, 2023, with all proposed resolutions being carried. The company is focused on developing paxalisib, an effective treatment for brain cancer, and is advancing multiple clinical trials. Additionally, the drug has received critical designations from the FDA, enhancing its development potential. Kazia is also pursuing other oncology-focused projects, including EVT801, which is under clinical investigation.
Read more →KZIAASX ANNOUNCEMENT 24 February 2023 CHANGE IN AUDITOR S y dn ey , 2 4 Fe b ru a r y 2 0 2 3 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), ( t h e C o m p a n y ), an oncology-focused drug development company, advise
Kazia Therapeutics Limited has announced the appointment of BDO Audit Pty Ltd as its new auditor following the resignation of Grant Thornton Audit Pty Ltd. This change is viewed as a measure of good corporate governance. The Board expressed gratitude to Grant Thornton for their years of service. Kazia continues to advance its oncology programs, specifically focusing on paxalisib for brain cancer treatment, which has shown promising efficacy in clinical trials.
Read more →KZIA▼ -14.3%on this newsshared move
KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS
Kazia Therapeutics Limited has announced a successful placement of shares to raise A$4.5 million aimed at advancing its R&D programs. The placement includes an unconditional component and a conditional component pending shareholder approval. The shares are priced at A$0.11 each, reflecting a premium over recent trading averages. The funds raised will support crucial stages in the company's clinical development, particularly the paxalisib GBM AGILE study, with immediate issuance of shares expected.
Read more →KZIAASX ANNOUNCEMENT 15 December 2022 KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING Sydney, 15 December 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX
PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Researc
Read more →KZIAKAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING
SYDNEY, Dec. 15, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to
Read more →KZIAKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
SYDNEY, Dec. 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC, dated December 9, 2022, notifying the company that it is not in compliance with the m
Read more →KZIADecember 2022 KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION Sydney , 12 D ecember 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications S
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION Sydney, 12 December 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC, dated December 9, 2022, notifying the
Read more →KZIA▲ +5.2%on this news
ASX ANNOUNCEMENT 1 December 2022 COMPELLING PRECLINICAL DATA FOR KAZIA S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL Sydney, 1 December 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-
COMPELLING PRECLINICAL DATA FOR KAZIA S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL Sydney, 1 December 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive precl
Read more →KZIA▲ +5.2%on this news
COMPELLING PRECLINICAL DATA FOR KAZIA
SYDNEY, Dec. 1, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial fo
Read more →KZIAASX RELEASE 16 November 2022 AGM MATERIALS Sydney, 16 November 2022 Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide the results of the Company s AG
Sydney, 16 November 2022 Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide the results of the Company s AGM, held earlier today. About Kazia Therapeutics Limited Kazia Therapeutics Limited (NASDAQ: KZIA; AS
Read more →KZIAKAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
SYDNEY, Nov. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an ora
Read more →KZIAASX ANNOUNCEMENT 3 November 2022 WITHDRAWAL OF RESOLUTION FROM AGM Sydney, 3 November 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, wishes to provide information
WITHDRAWAL OF RESOLUTION Sydney, 3 November 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, wishes to provide information in relation to the withdrawal of a resolution from the upcoming Annual General Meeting. Meeting, lo
Read more →KZIAKAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new...
SYDNEY, Oct. 27, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University
Read more →KZIAOctober 27 th , 2022 KAZIA S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA Sydney, October 27 th , 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA),
KAZIA S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA Sydney, October 27th, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new d
Read more →KZIA▼ -11.5%on this news
PNOC CLINICAL STUDY OF KAZIA
SYDNEY, Oct. 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that an ongoing phase II study of paxalisib, an investigational drug for the treatment of diffuse intrinsic pontine glioma (DIPG
Read more →KZIA▲ +5.1%on this news
A Diversified Oncology Drug Development Company Presentation to HC Wainwright Global Investment Conference New York, NY 14 September 2022 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx Forward-Looking Statements This presen
Presentation to HC Wainwright Global Investment Conference New York, NY 14 September 2022 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private
Read more →KZIAKAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the upcoming 24th Annual Global Investment Conference, held in New York
Read more →KZIAKAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
SYDNEY, Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an or
Read more →KZIAAppendix3Y Change of Director s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and document
Director s Interest Notice Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public. Introduced 30/09/01 Amended 01/01/11 INa
Read more →KZIA▼ -9.2%on this news
ANNUAL REPORT 2022 ANNUAL REPORT 2022 CONTENTS 2022 at a Glance 2 Chairman s Letter 4 CEO s Report 6 Key Milestones 8 Pipeline Review 10 Environment, Society & Governance 14 Our Collaborators 16 Financial Reports 20 The
ANNUAL REPORT 2022 CONTENTS 2022 at a Glance 2 Chairman s Letter 4 CEO s Report 6 Key Milestones 8 Pipeline Review 10 Environment, Society & Governance 14 Our Collaborators 16 Financial Reports 20 The journey of a young biotech company is often circuitous, but we have neverthel
Read more →KZIAKAZIA THERAPEUTICS RAPPORTE DES DONNÉES INTERMÉDIAIRES PROMETTEUSES TIRÉES D
SYDNEY, 6 août 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA ; ASX: KZA), une société de développement de médicaments axée sur l'oncologie, a le plaisir d'annoncer la présentation de nouvelles données prometteuses issues d'un essai clinique de phase I en cours sur
Read more →KZIAKAZIA THERAPEUTICS MELDET VIELVERSPRECHENDE ZWISCHENERGEBNISSE DER KOMBINATIONSSTUDIE VON PAXALISIB MIT STRAHLENTHERAPIE ZUR BEHANDLUNG VON HIRNMETASTASEN
SYDNEY, 6. August 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), ein auf die Entwicklung von Krebsmedikamenten spezialisiertes Unternehmen, freut sich, die Präsentation vielversprechender neuer Daten aus einer laufenden klinischen Phase-I-Studie mit Pax
Read more →KZIAKAZIA THERAPEUTICS INFORMA DE DATOS PROMETEDORES DEL ESTUDIO DE PAXALISIB CON RADIOTERAPIA
-KAZIA THERAPEUTICS INFORMA DE DATOS PROVISIONALES PROMETEDORES DEL ESTUDIO DE COMBINACIÓN DE PAXALISIB CON RADIOTERAPIA EN EL TRATAMIENTO DE LAS METÁSTASIS CEREBRALES SIDNEY, 5 de agosto de 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), una empresa de
Read more →KZIAKAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
SYDNEY, Aug. 5, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase I clinical trial of paxalisib in combination with radiothera
Read more →KZIAASX RELEASE 5 August 2022 KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES Sydney, 5 August 2022 Kazia Therapeutics Limited (NASDAQ:
KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN Sydney, 5 August 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the pres
Read more →KZIA▼ -47.1%on this news
ASX RELEASE 1 August 2022 KAZIA PROVIDES PROGRESS UPDATE ON GBM AGILE PIVOTAL STUDY Sydney, 1 August 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced today
KAZIA PROVIDES PROGRESS UPDATE ON GBM AGILE PIVOTAL STUDY Sydney, 1 August 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced today a progress update on the GBM AGILE pivotal study (NCT03970447), a global adaptive c
Read more →KZIAKAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
SYDNEY, July 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB consists of four distinguished clinicians and scientists
Read more →KZIAUS FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, July 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia'
Read more →KZIAASX RELEASE 17 June 2022 US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER Sydney, 17 June 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-foc
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER Sydney, 17 June 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food
Read more →KZIAUS FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib
Read more →KZIAPOSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
SYDNEY, June 13, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms of childhood brain cancer with poor progno
Read more →KZIAPHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metastases, led by the Alliance for Clinical Trial
Read more →KZIAKAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
SYDNEY, June 3, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The d
Read more →KZIAGBM AGILE OPENS TO PAXALISIB IN EUROPE
SYDNEY, May 31, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment to the paxalisib arm in Europe. University
Read more →KZIAKAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
SYDNEY, May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of
Read more →KZIAKAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE
SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased fo
Read more →KZIAKAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
SYDNEY, April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a po
Read more →KZIATWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company's investigational novel drug, EVT801, a
Read more →KZIAKAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the activity of paxalisib in two forms of childhood brain cancer with very high unmet
Read more →KZIAKAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. American Association of Cancer Research Annual Sci
Read more →KZIAPHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
SYDNEY, Feb. 28, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in combination with metformin and a ketogenic diet
Read more →KZIAKAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be held in person and virtually in New York,
Read more →KZIAKAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP
SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from 25-27 Janu
Read more →KZIAKAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 J
Read more →KZIAKAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER
SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and main
Read more →KZIAGBM AGILE Opens to Paxalisib in Canada
SYDNEY, Nov. 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health Sciences Centre in Tor
Read more →KZIAKazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseei
Read more →KZIAPNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the U
Read more →KZIAKazia Enrols First Patient to EVT801 Phase I Clinical Trial
SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licen
Read more →KZIAKazia Therapeutics to Present at LD Micro Main Event
SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from 12-14 O
Read more →KZIAKazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held
Read more →KZIAKazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and gov
Read more →KZIAKazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
SYDNEY, June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. GBM AGILE pivotal study of paxalisib is
Read more →KZIAKazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United
Read more →KZIAStudy of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-
Read more →KZIAKazia Therapeutics to Present at LD Micro Invitational XI
SYDNEY, June 3, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner, will be presenting virtually at the upcoming LD Micro Invitational XI. Dr Garner commented, "this is a par
Read more →KZIAKazia obtient de la part d
SYDNEY, 21 avril 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA ; NASDAQ: KZIA), une société de développement de médicaments axée sur l'oncologie, est heureuse d'annoncer qu'elle a conclu un accord de licence mondial exclusif et un contrat-cadre de services avec Evotec
Read more →KZIAKazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE
SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA:
Read more →KZIAKazia licencia los derechos globales de EVT801, un nuevo inhibidor clinic de VEGFR3, de Evotec SE
SIDNEY, 19 de abril de 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), una empresa de desarrollo de fármacos centrada en la oncología, se complace en anunciar que ha entrado en un acuerdo mundial de licencias exclusivas y un acuerdo de servicios maestros
Read more →KZIAKazia lizenziert globale Rechte an EVT801, einem neuartigen, klinisch einsetzbaren VEGFR3-Inhibitor, von Evotec SE
SYDNEY, 20. April 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), ein auf die Entwicklung von Krebsmedikamenten spezialisiertes Unternehmen, freut sich bekannt zu geben, dass es eine weltweite exklusive Lizenzvereinbarung und einen Rahmenvertrag für Dien
Read more →KZIAKazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company
SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop
Read more →KZIAKazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG
SYDNEY, Dec. 10, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to launch a
Read more →KZIAKazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) in the United States, to inve
Read more →KZIAKazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data...
SYDNEY, April 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most co
Read more →KZIAPositive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most a
Read more →KZIAKazia calls for greater awareness of the deadliest brain cancer in the US
SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the most lethal brain cancer in the US. Glioblastoma (GBM) is the most common, comp
Read more →KZIAKazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
SYDNEY, May 20, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance),
Read more →KZIAKazia calls for greater awareness of the deadliest gynecological cancer in the US
SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women wil
Read more →KZIAKazia Presents Positive Cantrixil Phase I Data at AACR Conference
SYDNEY, April 1, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation summarising data from Part A of the ongoing phase I study of Cantrixil (TRX-
Read more →KZIAProgress Update on GDC-0084 Program
SYDNEY, Oct. 29, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an update to shareholders regarding progress with GDC-0084, which is currently in human trials for glioblastoma a
Read more →KZIAKazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
SYDNEY, Oct. 22, 2018 /PRNewswire/ -- The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia's potential new therapy for brai
Read more →KZIACantrixil Phase I Study Progresses To Next Stage
SYDNEY, Oct. 10, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the successful completion of Part A, the dose escalation component, of its phase I study of Cantrixil in ovarian
Read more →KZIAKazia Releases Preliminary Cantrixil Phase I Data
SYDNEY, June 19, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or
Read more →KZIACommencement de l
SYDNEY, 29 mars 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX : KZA ; NASDAQ : KZIA), société australienne de développement de médicaments oncologiques, a le plaisir d'annoncer le début d'un essai clinique international en phase II dans le cadre de son programme directeur
Read more →KZIAStart der klinischen Phase-II-Studie von GDC-0084
Sydney, 29. März 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA), ein australisches Unternehmen zur Entwicklung onkologischer Medikamente, meldet den Beginn einer internationalen Phase-II-Studie seines Leitprogramms GDC- 0084. Die wichtigsten Punkte Der
Read more →KZIACommencement Of Phase II Clinical Study Of GDC-0084
SYDNEY, March 28, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology drug development company, is pleased to announce commencement of an international phase II clinical trial of its lead program, GDC-0084. First site, Stephenson Canc
Read more →KZIAKazia erhält Orphan-Kennzeichnung der FDA für GDC-0084
SYDNEY, 24. Februar 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), ein australisches Biotechnologie-Unternehmen mit Schwerpunkt auf Onkologie, freut sich, bekannt geben zu dürfen, dass die US-amerikanische Food and Drug Administration (FDA) die Kennzeic
Read more →KZIAKazie recibe de la FDA la designación de medicamento huérfano para el GDC-0084
SÍDNEY, 24 de febrero de 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA), empresa biotecnológica australiana dedicada al ámbito de la oncología, se complace en anunciar que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha conce
Read more →KZIAKazia reçoit la désignation de médicament orphelin de la FDA pour le GDC-0084
SYDNEY, 23 février 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX : KZA; NASDAQ : KZIA), une société australienne de biotechnologie se consacrant à l'oncologie, est heureuse d'annoncer que la Food and Drug Administration (FDA, l'agence américaine des produits alimentaires e
Read more →KZIAKazia Receives FDA Orphan Designation for GDC-0084
SYDNEY, Feb. 23, 2018 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's i
Read more →KZIANovogen Announces Results of General Meeting of Shareholders SYDNEY
Novogen Announces Results of General Meeting of Shareholders SYDNEY, Aug. 13, 2014 /PRNewswire/ -- Australia-US biotechnology company, Novogen Ltd. (ASX: NRT, NASDAQ: NVGN), an oncology and degenerative diseases drug development company, today announced the results of its Genera
Read more →KZIANovogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 Yale researc
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 Yale researchers present the latest in vitro and in vivo results at Dr
Read more →KZIANovogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases SYDNEY
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases SYDNEY, May 2, 2014 /PRNewswire/ -- Novogen Limited (NASDAQ: NVGN, ASX: NRT;), an oncology drug development company, today announced a collaboration with Australian company
Read more →KZIANovogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo Experimental drug designed to fight abdominal cancers passes important test SYDNEY
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo Experimental drug designed to fight abdominal cancers passes important test SYDNEY, March 18, 2014 /PRNewswire/ -- Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, Can
Read more →KZIAASX MEDIA RELEASE 2 MAY, 2011 MARSHALL EDWARDS ANNOUNCES PRIVATE PLACEMENT Novogen Limited s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement. San Diego 2 May, 2011 Marshall Edwards,
MARSHALL EDWARDS ANNOUNCES PRIVATE PLACEMENT Novogen Limited s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following San Diego 2 May, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics t
Read more →Competitive Position
How KZIA ranks across every disease it competes inCompetitive Position is a premium feature
See how KZIA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial